Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis

References

• Gordon M Naidoo K Thomas AG Akobeng AK Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease Cochrane Database Syst Rev 2011 CD008414 21249709
   PubMed Web of Science ®Google Scholar
• Baan B Dihal AA Hoff E 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer Gut 2012 61 12 1708 1715 22187071
   PubMed Web of Science ®Google Scholar
• Koelink PJ Hawinkels LJ Wiercinska E 5-Aminosalicylic acid inhibits TGF-beta1 signalling in colorectal cancer cells Cancer Lett 2010 287 1 82 90 19541409
   PubMed Web of Science ®Google Scholar
• Velayos FS Terdiman JP Walsh JM Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies Am J Gastroenterol 2005 100 6 1345 1353 15929768
   PubMed Web of Science ®Google Scholar
• Bonner GB Ruderman WB 5-Aminosalicylic acid preparations in the treatment of inflammatory bowel disease Inflammopharmacology Norwell, Mass Kluwer Academic 1993 247 262
   Google Scholar
• Brzezinski A Rankin GB Seidner DL Lashner BA Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease Cleve Clin J Med 1995 62 5 317 323 7586488
   PubMed Web of Science ®Google Scholar
• Fernandez-Becker NQ Moss AC Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes Drugs 2008 68 8 1089 1103 18484800
   PubMed Web of Science ®Google Scholar
• Brown JP McGarraugh GV Parkinson TM Wingard REJr Onderdonk AB A polymeric drug for treatment of inflammatory bowel disease J Med Chem 1983 26 9 1300 1307 6136612
   PubMed Web of Science ®Google Scholar
• Campbell DE Berglindh T Pharmacology of olsalazine Scand J Gastroenterol Suppl 1988 148 7 12 3067340
   PubMedGoogle Scholar
• Riley SA Turnberg LA Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease Q J Med 1990 75 278 551 562 1977185
   PubMedGoogle Scholar
• Mahmud N Kamm MA Dupas JL Olsalazine is not superior to placebo in maintaining remission of inactive Crohn’s colitis and ileocolitis: a double blind, parallel, randomised, multicentre study Gut 2001 49 4 552 556 11559654
   PubMed Web of Science ®Google Scholar
• Rao SS Read NW Holdsworth CD Influence of olsalazine on gastrointestinal transit in ulcerative colitis Gut 1987 28 11 1474 1477 3428673
   PubMed Web of Science ®Google Scholar
• Sutherland LR Roth DE Beck PL Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative Colitis Inflamm Bowel Dis 1997 3 2 65 78 23282747
   PubMed Web of Science ®Google Scholar
• Epifano F Genovese S Carlucci G Locatelli M Novel prodrugs for the treatment of colonic diseases based on 5-aminosalicylic acid, 4′-geranyloxyferulic acid, and auraptene: biological activities and analytical assays Curr Drug Deliv 2012 9 2 112 121 22283649
   PubMed Web of Science ®Google Scholar
• Dhaneshwar SS Gairola N Kandpal M Bhatt L Vadnerkar G Kadam SS Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid with D-phenylalanine for colon specific drug delivery in inflammatory bowel disease Bioorg Med Chem Lett 2007 17 7 1897 1902 17280832
   PubMed Web of Science ®Google Scholar
• Wiwattanapatapee R Lomlim L Saramunee K Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid J Control Release 2003 88 1 1 9 12586498
   PubMed Web of Science ®Google Scholar
• Dunwell DW Evans D Synthesis and antiinflammatory activity of some 2-aryl-6-benzoxazoleacetic acid derivatives J Med Chem 1977 20 6 797 801 874954
   PubMed Web of Science ®Google Scholar
• Bekhit AA Khalil MA Non-steroidal anti-inflammatory agents: synthesis of novel benzopyrazolyl, benzoxazolyl and quinazolinyl derivatives of 4(3 H)-quinazolinones Pharmazie 1998 53 8 539 543 9741062
   PubMed Web of Science ®Google Scholar
• Kumar D Jacob MR Reynolds MB Kerwin SM Synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1 Bioorg Med Chem 2002 10 12 3997 4004 12413851
   PubMed Web of Science ®Google Scholar
• Huang ST Hsei IJ Chen C Synthesis and anticancer evaluation of bis(benzimidazoles), bis(benzoxazoles), and benzothiazoles Bioorg Med Chem 2006 14 17 6106 6119 16714116
   PubMed Web of Science ®Google Scholar
• Oksuzoglu E Tekiner-Gulbas B Alper S Some benzoxazoles and benzimidazoles as DNA topoisomerase I and II inhibitors J Enzyme Inhib Med Chem 2008 23 1 37 42 18341251
   PubMed Web of Science ®Google Scholar
• Yang Z Fairfax DJ Maeng JH Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists Bioorg Med Chem Lett 2010 20 22 6538 6541 20889341
   PubMed Web of Science ®Google Scholar
• Cashin CH Dawson W Kitchen EA The pharmacology of benoxaprofen (2-[4-chlorophenyl]-alpha-methyl-5-benzoxazole acetic acid), LRCL 3794, a new compound with antiinflammatory activity apparently unrelated to inhibition of prostaglandin synthesis J Pharm Pharmacol 1977 29 6 330 336 18568
   PubMed Web of Science ®Google Scholar
• Dunwell DW Evans D Hicks TA Synthesis and antiinflammatory activity of some 2-heteroaryl-alpha-methyl-5-benzoxazoleacetic acids J Med Chem 1975 18 11 1158 1159 1177263
   PubMed Web of Science ®Google Scholar
• Dawson W The comparative pharmacology of benoxaprofen J Rheumatol Suppl 1980 6 5 11 6771399
   PubMedGoogle Scholar
• Egan RW Gale PH Comparative biochemistry of lipoxygenase inhibitors Bailey JM Prostaglandins, Leukotrienes and Lipoxins (Contemporary Issues in Risk Analysis) New York, NY Springer 1985 593 607
   Google Scholar
• Allen BR Littlewood SM The aetiology of psoriasis: clues provided by benoxaprofen Br J Dermatol 1983 109 Suppl 25 126 129 6305387
   PubMed Web of Science ®Google Scholar
• Bosman B Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis Skin Pharmacol 1994 7 6 324 334 7946375
   PubMedGoogle Scholar
• Hawkey CJ Rampton DS Benoxaprofen in the treatment of active ulcerative colitis Prostaglandins Leukot Med 1983 10 4 405 409 6407032
   PubMedGoogle Scholar
• Wallace JL MacNaughton WK Morris GP Beck PL Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease Gastroenterology 1989 96 1 29 36 2535830
   PubMed Web of Science ®Google Scholar
• Uekama K Minami K Hirayama F 6A-O-[(4-biphenylyl)acetyl]-alpha-, -beta-, and -gamma-cyclodextrins and 6A-deoxy-6A-[[(4-biphenylyl)acetyl]amino]-alpha-, -beta-, and -gamma-cyclodextrins: potential prodrugs for colon-specific delivery J Med Chem 1997 40 17 2755 2761 9276021
   PubMed Web of Science ®Google Scholar
• Morris GP Beck PL Herridge MS Depew WT Szewczuk MR Wallace JL Hapten-induced model of chronic inflammation and ulceration in the rat colon Gastroenterology 1989 96 3 795 803 2914642
   PubMed Web of Science ®Google Scholar
• Morris GP Rebeiro L Herridge MM Szewczuk M Depew W An animal model of chronic granulomatous inflammation of the stomach and colon Gastroenterology 1984 86 1188
   Web of Science ®Google Scholar
• Stephens FF Bower JD 626. The preparation of benziminazoles and benzoxazoles from Schiff’s bases. Part I J Chem Soc 1949 1949 2971 2972
   Web of Science ®Google Scholar
• Stephens FF Bower JD 348. The preparation of benziminazoles and benzoxazoles from Schiff’s bases. Part II J Chem Soc 1950 1950 1722 1726
   Web of Science ®Google Scholar
• Wadworth AN Fitton A Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease Drugs 1991 41 4 647 664 1711964
   PubMed Web of Science ®Google Scholar